Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 12

-Sentence Column A

+ Details

Name:	invest_InvestmentLineItems
Namespace Prefix:	invest_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity method investment amount of shares purchased.

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentAmountOfSharesPurchased
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Proceeds to be received from sale of proprietary technology

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentNoteReceivableCashOption
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Equity Method Investment, Note Receivable, Share Option

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentNoteReceivableShareOption
Namespace Prefix:	opk_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity method investment number of shares purchased.

+ References

No definition available.

+ Details

Name:	opk_EquityMethodInvestmentNumberOfSharesPurchased
Namespace Prefix:	opk_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Research funding and option agreement period of payment.

+ References

No definition available.

+ Details

Name:	opk_RelatedPartyTranscationAgreementTermsFutherDevelopmentofTechnologyMaturityPeriod
Namespace Prefix:	opk_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Received From Collaboration Agreement, Offset to Research and Development

+ References

No definition available.

+ Details

Name:	opk_RevenueReceivedFromCollaborationAgreementOffsettoResearchandDevelopment
Namespace Prefix:	opk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Shares Received In Satisfaction of Notes Receivable

+ References

No definition available.

+ Details

Name:	opk_SharesReceivedInSatisfactionofNotesReceivable
Namespace Prefix:	opk_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions, Investments, and Licenses - Pharmsynthez transactions Narrative (Details) shares in Millions, RUB in Millions, $ in Millions	1 Months Ended			6 Months Ended		12 Months Ended
	Jan. 31, 2014 shares	Apr. 30, 2013 USD ($) shares	Apr. 30, 2013 RUB shares	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2014 USD ($)
Investment [Line Items]
Deferred revenue				$ 272.4			$ 6.7
Pharmsynthez
Investment [Line Items]
Asset purchase agreement		$ 9.6
Number of shares purchased \| shares		13.6	13.6
Number of share options received in purchase agreement \| shares		12.0	12.0
Proceeds to be received from sale of proprietary technology			RUB 265.0			$ 8.1
Shares received in satisfaction of notes receivable \| shares	12.0
Deferred revenue		$ 9.5
Period for development of technology		3 years	3 years
Revenue related to our license agreements				0.0	$ 0.5
Revenue collaboration agreement, offset to research and development				$ 0.5	$ 0.8